While PDE5 inhibitors are in wide clinical use for the treatment of pulmonary hypertension, benign prostate hyperplasia and erectile dysfunction [6] through their vasorelaxation action, growing evidence has suggested that PDE5 inhibition also provide beneficial cardiac effects. This evidence concerns the gene PDE5A and benign prostatic hyperplasia.